STAT

Opinion: Bots started sabotaging my online research. I fought back

I launched an online study aimed at understanding what influences eating behaviors and eating disorders among individuals who identify as in LGBTQ+. Little did I know I was actually launching…

I launched an online study earlier this year aimed at understanding the processes that influence eating behaviors and eating disorders among individuals who identify as LGBTQ+. Little did I know I was actually launching a battle with bots.

Online surveys and questionnaires let researchers like me collect large, geographically diverse samples relatively quickly. With the growing availability of machine learning and other big-data methods, there are few easier and more cost-efficient ways to collect data. But these tools have become targets for bots and professional survey takers, which are flooding online research and threatening data integrity.

That threat wasn’t on my mind when my study went live. It consisted of validated self-report questions to measure eating disorder behaviors, exposure to discrimination, psychological well-being, social support, and a number of demographic variables. I was interested in whether sexual orientation and gender influenced eating in ways that we have not yet conceptualized, so I developed a set of

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks